Clinical Trials Logo

Filter by:
NCT ID: NCT01700088 Completed - Hypoxia Clinical Trials

The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy

Start date: November 2012
Phase: N/A
Study type: Observational

At our institute,during the first 2 hour postoperative, we used to give supplement oxygen via face mask in patient having lung resection surgery. After then if the patient is fine, we'll replace the face mask with nasal cannular untie the next morning. We hypothesized that oxygen mask can be replace by nasal cannular without any hypoxia.

NCT ID: NCT01698918 Completed - Clinical trials for Hormone Receptor Positive Breast Cancer

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

BOLERO-4
Start date: March 7, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. Moreover, the study also aimed to investigate the efficacy and safety of second line treatment with everolumus plus examestane in participants whose disease progressed during everolimus plus letrozole therapy.

NCT ID: NCT01688843 Completed - Bradycardia Clinical Trials

Safety and Performance Study of the INGEVITY Lead

Start date: October 2012
Phase: N/A
Study type: Interventional

The objective of this study is to gather data to establish the safety, performance and effectiveness of the INGEVITY pace/ sense leads.

NCT ID: NCT01687218 Completed - HIV Clinical Trials

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Start date: September 25, 2013
Phase: Phase 2
Study type: Interventional

MTN-017 is a Phase 2, multi-site, randomized, six-sequence, two three-period, open label crossover study, examining the effects of oral Truvada and reduced glycerin 1% tenofovir gel. The study population will be sexually active, HIV-uninfected males who are 18 years of age or older, who report a history of receptive anal intercourse in the past 3 months. Each of the study product regimens offers different advantages to participants seeking an effective HIV prevention agent. How these relative advantages will compare in terms of safety, acceptability, systemic and local absorption, and adherence will be examined within this study.

NCT ID: NCT01686022 Completed - Clinical trials for Allergy to Grass Pollen

Grass Sensitisation and Allergic Rhinitis in Thai Patients

Start date: October 2012
Phase: N/A
Study type: Observational

Allergic rhinitis patients are the patients who have nasal symptoms when triggered by indoor or outdoor allergens. Outdoor allergen can be divided into grass, tree, or weed. The type of grass or weed are different in various part of the world. The allergens from grass and weed has never been studied in Thailand. This study will find the major allergen from Bermuda grass, Johnson grass, Para grass, sedge, and ragweed, which are very common in Thailand. In addition, the investigators will study about the cross-reactivity among these group of allergen.

NCT ID: NCT01685398 Completed - Hemangioma Clinical Trials

Topical Timolol for Superficial Infantile Hemangioma

Start date: September 2012
Phase: Phase 3
Study type: Interventional

Infantile hemangioma (IH) is the most common benign vascular tumor in pediatric population. The characteristic natural history of this tumor is rapid growth in the first year of life and follows by spontaneous involution. However, it may cause cosmetic unacceptable. Early intervention in superficial IH may help to minimize the risk of residual aesthetic problems. Topical timolol, a non selective beta-blocker, is an emerging treatment which has been reported in efficacy and safety for the treatment of IH. However, the reported studies were case-series or small study. This study is a prospective double-blind,randomized-controlled study to evaluate the efficacy and safety of 0.5% timolol maleate solution for treatment in superficial IH. The patient will be treated with topical timolol for at least 6 months and instructed to 4 times daily apply 1-2 drop of timolol solution on the lesion and rub over the entire lesion with a finger. Photographs of the lesion will be taken at the baseline and every 1-month visit. Clinical evaluation of the treatment efficacy is carried out by 2 investigators independently to determine the change in lesion size and visual analogue scale of the lesion color. The main outcome is to evaluate the efficacy of 0.5% timolol maleate solution in treatment of infantile hemangioma compared to placebo.

NCT ID: NCT01685138 Completed - Clinical trials for Non-Small Cell Lung Cancer

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Start date: December 20, 2012
Phase: Phase 2
Study type: Interventional

A single-arm, open-label, two-stage multicenter, phase II study. Patients were pre-screened for ALK positive status. Treatment with LDK378 at 750 mg qd was continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of the investigator or patient, started a new anticancer therapy and/or died. LDK378 was continued beyond RECIST defined progressive disease (PD) as assessed by the investigator, if in the judgment of the investigator, there was evidence of clinical benefit. Patients who discontinued the study medication in the absence of progression continued to be followed for tumor assessment until the time of PD as assessed by the investigator. Male and female patients aged 18 or over with ALK-rearranged non-small cell cancer (NSCLC) were screened for eligibility. Patients had to have received no prior crizotinib, and had to be chemotherapy-naïve or been pretreated with cytotoxic chemotherapy (up to three prior lines).

NCT ID: NCT01681992 Completed - Measles Clinical Trials

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Start date: October 10, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck & Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).

NCT ID: NCT01681355 Completed - Healthy Infants Clinical Trials

Gastrointestinal Tolerance Study of a New Infant Formula

BOOGIE
Start date: September 2012
Phase: N/A
Study type: Interventional

This study is initiated to investigate the gastrointestinal tolerance of a new infant formula in healthy, term, Asian infants.

NCT ID: NCT01672307 Completed - Thinning Eyebrows Clinical Trials

Minoxidil 2% for Eyebrow Enhancement

Start date: September 2012
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare minoxidil 2% versus placebo in enhancement of eyebrows.